Aclaris Therapeutics Inc. (ACRS) Major Shareholder Ra Capital Management, Llc Sells 525,550 Shares
Aclaris Therapeutics Inc. (NASDAQ:ACRS) major shareholder Ra Capital Management, Llc sold 525,550 shares of the company’s stock in a transaction that occurred on Friday, September 16th. The stock was sold at an average price of $24.19, for a total value of $12,713,054.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Aclaris Therapeutics Inc. (NASDAQ:ACRS) opened at 23.80 on Tuesday. The stock’s 50 day moving average price is $20.92 and its 200 day moving average price is $19.65. The company’s market cap is $509.68 million. Aclaris Therapeutics Inc. has a 52-week low of $10.99 and a 52-week high of $33.88.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Thursday, August 11th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.61) by $0.01. Analysts expect that Aclaris Therapeutics Inc. will post ($2.61) earnings per share for the current year.
Hedge funds have recently bought and sold shares of the company. Nationwide Fund Advisors raised its stake in shares of Aclaris Therapeutics by 47.0% in the second quarter. Nationwide Fund Advisors now owns 5,747 shares of the company’s stock valued at $106,000 after buying an additional 1,838 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in shares of Aclaris Therapeutics by 24.3% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 28,286 shares of the company’s stock valued at $536,000 after buying an additional 5,535 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Aclaris Therapeutics by 18.3% in the first quarter. Geode Capital Management LLC now owns 43,246 shares of the company’s stock valued at $819,000 after buying an additional 6,679 shares during the last quarter. California State Teachers Retirement System raised its stake in shares of Aclaris Therapeutics by 54.7% in the second quarter. California State Teachers Retirement System now owns 18,896 shares of the company’s stock valued at $349,000 after buying an additional 6,683 shares during the last quarter. Finally, Geduld E E raised its stake in shares of Aclaris Therapeutics by 62.5% in the second quarter. Geduld E E now owns 17,500 shares of the company’s stock valued at $323,000 after buying an additional 6,729 shares during the last quarter. 71.39% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages have recently issued reports on ACRS. Zacks Investment Research cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 24th. Jefferies Group upped their price objective on Aclaris Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a report on Monday. Finally, Guggenheim began coverage on Aclaris Therapeutics in a report on Friday, June 10th. They set a “buy” rating and a $35.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $31.25.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.